Emily Hoedt

BACKGROUND: Our team (Xiong et al. 2021) recently developed an infliximab population pharmacokinetic (popPK) model in children and young adults with Crohn’s disease (CD). We found that prediction accuracy improved when all five covariates of drug clearance were included…

BACKGROUND: Despite rapidly increasing global burden of metabolic-associated fatty liver disease (MAFLD), therapeutic options remain limited. Dietary modulation is a key component of MAFLD management, with reduced energy intake for weight loss considered first line therapy…